Eledon Pharmaceuticals Enters Material Definitive Agreement
Ticker: ELDN · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1404281
| Field | Detail |
|---|---|
| Company | Eledon Pharmaceuticals, Inc. (ELDN) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $1.65, $1.649, $46.5 million, $53.6 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
TL;DR
Eledon Pharma signed a big deal on Nov 12, 2025. Details to follow.
AI Summary
Eledon Pharmaceuticals, Inc. entered into a Material Definitive Agreement on November 12, 2025. The company, formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing indicates a significant new agreement for Eledon Pharmaceuticals, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — The nature of the Material Definitive Agreement is not specified, introducing uncertainty about its impact.
Key Players & Entities
- Eledon Pharmaceuticals, Inc. (company) — Registrant
- November 12, 2025 (date) — Date of earliest event reported
- Novus Therapeutics, Inc. (company) — Former company name
- Tokai Pharmaceuticals Inc (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Irvine, California (location) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Eledon Pharmaceuticals?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on November 12, 2025.
When was the Material Definitive Agreement entered into?
The Material Definitive Agreement was entered into on November 12, 2025.
What were Eledon Pharmaceuticals' former company names?
Eledon Pharmaceuticals, Inc. was formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc.
Where are Eledon Pharmaceuticals' principal executive offices located?
Eledon Pharmaceuticals' principal executive offices are located at 19800 MacArthur Blvd., Suite 250, Irvine, California.
What is the SIC code for Eledon Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Eledon Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,158 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2025-11-12 20:55:33
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value ELDN Nasdaq Capital Marke
- $1.65 — n Stock") at a public offering price of $1.65 per share (the "Common Stock Purchase P
- $1.649 — arrants") at a public offering price of $1.649 per Pre-Funded Warrant, which are exerc
- $46.5 million — ed offering expenses, are approximately $46.5 million (which may increase to approximately $5
- $53.6 million — on (which may increase to approximately $53.6 million if the Underwriters exercise the Option
Filing Documents
- d28785d8k.htm (8-K) — 31KB
- d28785dex11.htm (EX-1.1) — 265KB
- d28785dex41.htm (EX-4.1) — 73KB
- d28785dex51.htm (EX-5.1) — 18KB
- g28785g1112131230292.jpg (GRAPHIC) — 2KB
- 0001193125-25-278392.txt ( ) — 604KB
- eldn-20251112.xsd (EX-101.SCH) — 3KB
- eldn-20251112_lab.xml (EX-101.LAB) — 18KB
- eldn-20251112_pre.xml (EX-101.PRE) — 11KB
- d28785d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated November 12, 2025, by and between Eledon Pharmaceuticals, Inc. and Leerink Partners LLC, as representative of the several underwriters named therein. 4.1 Form of Pre-Funded Warrant. 5.1 Legal Opinion of O'Melveny & Myers LLP, dated November 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Eledon Pharmaceuticals, Inc. Date: November 12, 2025 By: /s/ David-Alexandre C. Gros, M.D. Name: David-Alexandre C. Gros, M.D. Title: Chief Executive Officer